ロード中...
Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation
BACKGROUND: Phase III trials evaluating the efficacy of gefitinib (IRESSA) in non-small cell lung cancer (NSCLC) lend support to the need for improved patient selection in terms of gefitinib use. Mutation of the epidermal growth factor receptor (EGFR) gene is reported to be associated with clinical...
保存先:
| 主要な著者: | , , , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2006
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1698934/ https://ncbi.nlm.nih.gov/pubmed/17150102 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-6-277 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|